Novavax starts new clinical trial in bid to prove failed RSV vaccine

Novavax isn't ready to give up just yet on what was once its most promising vaccine candidate — turned stunning failure last fall. On Thursday, Gaithersburg-based Novavax (NASDAQ: NVAX) announced it started a new phase 2 clinical trial of the product, a vaccine candidate for respiratory synctial virus, or RSV, in older adults. The trial, which will enroll up to 300 older adults in the sou thern hemisphere, is meant to test the safety and ability of the vaccine candidate to provoke an immune response…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news